Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 diabetes lose an average of nearly 8% of their body weight after 40 weeks and lowered their A1C levels.

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily weight loss pill, orforglipron, demonstrated effectiveness consistent with other injectable GLP-1 weight loss drugs, such as Lilly’s Mounjaro and Novo Nordisk’s Ozempic.

Fact checked by Nick Blackmer A daily GLP-1 pill can help people with type 2 diabetes regulate their blood sugar and lose weight, drugmaker Eli Lilly announced on Thursday. The readout comes just days after Pfizer announced it would abandon its own oral GLP-1 drug candidate due to worrying side effects.